Related Experiment Video

Updated: May 3, 2026

Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

19.7K

Attainment of diabetes-related quality measures with canagliflozin versus sitagliptin

Robert A Bailey1, C V Damaraju, Silas C Martin

  • 11000 US Route 202 South, Raritan, NJ 08869.

The American Journal of Managed Care
|February 12, 2014
PubMed
Abstract

Insights

Canagliflozin improved diabetes quality measures more than sitagliptin in type 2 diabetes patients on metformin and sulfonylurea. This included better control of A1C, blood pressure, and weight loss.

Area of Science:

  • Endocrinology
  • Metabolic Diseases
  • Pharmacology

Background:

  • Type 2 diabetes mellitus (T2DM) management requires comprehensive quality measures.
  • Sodium glucose cotransporter 2 (SGLT2) inhibitors offer a therapeutic option for T2DM.
  • Comparing SGLT2 inhibitors with dipeptidyl peptidase-4 (DPP-4) inhibitors is crucial for treatment optimization.

Purpose of the Study:

  • To compare the effectiveness of canagliflozin versus sitagliptin in achieving diabetes-related quality measures.
  • To evaluate attainment of glycemic, blood pressure, lipid, and weight targets in T2DM patients.
  • To assess treatment outcomes in patients receiving metformin plus sulfonylurea.

Main Methods:

  • Post hoc analysis of a 52-week, randomized, double-blind, phase 3 clinical trial.
  • Patients with T2DM on metformin plus sulfonylurea received either canagliflozin 300 mg or sitagliptin 100 mg.
  • Quality measures included glycated hemoglobin (A1C), blood pressure (BP), LDL cholesterol (LDL-C), body mass index (BMI), and body weight.

Main Results:

  • Canagliflozin treatment led to significantly higher achievement of A1C targets (<8%, <7%) and lower rates of A1C >9% compared to sitagliptin.
  • More patients achieved target blood pressure levels (<140/90, <140/80, <130/80 mm Hg) with canagliflozin.
  • Canagliflozin was associated with greater weight loss and a higher proportion of patients achieving a BMI <30 kg/m².
  • Composite endpoints including A1C, BP, and LDL-C were more frequently met with canagliflozin.

Conclusions:

  • Canagliflozin demonstrated superior attainment of individual and composite diabetes-related quality measures compared to sitagliptin in T2DM patients on dual therapy.
  • These findings support canagliflozin as an effective treatment option for improving multiple health parameters in T2DM.
  • The benefits were consistent in patients with a baseline BMI ≥25 kg/m².

More Related Videos

Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes07:22

Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes

Published on: March 7, 2025

1.2K
Quantification of Diabetes-induced Adherent Leukocytes in Retinal Vasculature05:54

Quantification of Diabetes-induced Adherent Leukocytes in Retinal Vasculature

Published on: January 24, 2025

798

Related Concept Videos

Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
1.1K
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.3K
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
1.0K
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
993
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
1.5K
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
4.9K